Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 G3, Sanofi Partner to Identify Heart Disease Targets | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances

G3, Sanofi Partner to Identify Heart Disease Targets

Aims to identify new signaling pathways in atherosclerotic cardiovascular diseases

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Global Genomics Group (G3) has entered into a research collaboration with Sanofi to identify new signaling pathways and targets involved in coronary artery disease. G3 will receive undisclosed payments from Sanofi under the collaboration.  

The companies will use G3’s platform with data from its G3LOBAL Database to further decipher the molecular underpinnings of LDL-cholesterol regulation and to better understand which patients may benefit from interference with these signaling pathways.

“Our G3LOBAL Database has been developed as a tool that enables drug developers and biomedical research scientists to better understand molecular networks that underlie human disease and thus improve the drug discovery and development process,” said Szilard Voros, M.D., founder and chief executive officer of G3. “We believe that precision phenotyping, pan-omics and systems-biology driven bioinformatics are the key components of target identification, validation and the elucidation of novel pathways.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics